WHEN YOU CHOOSE RIABNI®

AMGEN OFFERS PERSONALIZED SUPPORT FOR YOUR PATIENTS

Riabni® is A rituximab biosimilar that provides the Amgen level of support to your patients and practice

Riabni® is A rituximab biosimilar that provides the Amgen level of support to your patients and practice

RIABNI® is FDA approved for all Rituxan® oncology indications1,2

    *When diluted in 0.9% Sodium Chloride injection, USP

  • FDA = Food and Drug Administration.
  • Non-Hodgkin's lymphoma (NHL)
    • - Follicular lymphoma (FL)
    • - Previously untreated large B-cell lymphoma
    • - Non-progressing (stable disease)
  • Previously untreated chronic lymphocytic leukemia (CLL)

    *When diluted in 0.9% Sodium Chloride injection, USP

  • FDA = Food and Drug Administration.

RIABNI™
(rituximab-arrx) has an
established Q-Code:

Q5123
RIABNI RIABNI

RIABNI™ has reached pass-through status

×
Amgen stands with our local Los Angeles community. Click here to learn what we are doing to support and contact us if the fires have impacted your access to Amgen medication.